
Partners
With currently 20 international partners and 14 former partners, the EU Lead Factory capitalises on the innovation of academia, the agility of small- and medium-sized enterprises (SMEs) and the experience and resources of the large pharmaceutical partners that are members of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Governance and funding
The European Lead Factory is funded by the Innovative Medicines Initiative (IMI) Joint Undertaking, and by the IMI2 Joint Undertaking under ‘ESCulab: European Screening Centre; Unique Library for Attractive Biology’. The Joint Undertaking receives support from the EU’s Horizon 2020 research and innovation programme, and EFPIA and the Medicines for Malaria Venture (MMV). The 8 pharmaceutical partners provide in-kind contributions. The European Lead Factory is governed by the Project Management Board and the Project General Assembly. Lygature is the project coordinator and Bayer the project leader.
Interested?
Find out how you can boost your drug discovery programme and submit your screening proposal today
Latest news
Phenotypic screening is a powerful approach to identifying novel chemical starting points for drug discovery. It uses cell-based assays and advanced data analytics to develop quantitative fingerprints that can uncover new drug targets and pathways underpinning disease-related biology.
How to optimise your assay for High Throughput Screening (HTS) at the European Lead Factory (ELF). This was the topic of the latest ELF webinar, which took place on Thursday 28 January.